MedPath

Cysteamine Advanced Drug Monograph

Published:Aug 5, 2025

Generic Name

Cysteamine

Brand Names

Cystagon, Cystaran, Procysbi, Cystadrops

Drug Type

Small Molecule

Chemical Formula

C2H7NS

CAS Number

60-23-1

Associated Conditions

Cystinosis, Nephropathic, Corneal cystine crystal accumulation

Comprehensive Monograph: Cysteamine

Executive Summary

Cysteamine is a small molecule aminothiol that serves as the foundational, life-sustaining therapy for cystinosis, a rare and severe lysosomal storage disease. As a cystine-depleting agent, its primary mechanism of action involves a thiol-disulfide interchange reaction within the lysosome, which breaks down the accumulated, insoluble cystine into more soluble compounds that can be cleared from the cell, thereby preventing or delaying the catastrophic multi-organ damage characteristic of the disease. The therapeutic journey of Cysteamine is a notable example of pharmaceutical lifecycle management, evolving from an initial immediate-release oral formulation (Cystagon®) with a burdensome dosing schedule to a more patient-centric, delayed-release oral formulation (Procysbi®) and from a frequently administered ophthalmic solution (Cystaran®) to a more convenient viscous eye drop (Cystadrops®). These advancements have significantly improved treatment adherence and patient quality of life. While highly effective, Cysteamine possesses a significant safety profile that requires careful management, including risks of gastrointestinal distress, severe skin and bone lesions at high doses, and central nervous system effects. The drug's interaction profile is largely dependent on its formulation, with the delayed-release product being particularly sensitive to agents that alter gastric pH. Beyond its established role in cystinosis, Cysteamine is the subject of extensive research for new applications, most prominently in dermatology as a topical depigmenting agent for conditions like melasma and post-inflammatory hyperpigmentation, positioning it as a molecule with an expanding and promising therapeutic future.

Drug Identification and Chemical Profile

A comprehensive understanding of Cysteamine begins with its fundamental identity, encompassing its various names, unique identifiers across scientific databases, and its core chemical and physical properties.

Nomenclature and Identifiers

Cysteamine is known by a variety of names and is cataloged under numerous identifiers, reflecting its long history as a biological metabolite, research chemical, and therapeutic agent.

  • Generic and Chemical Names: The established generic name is Cysteamine.[1] Its International Nonproprietary Name (INN) is mercaptamine.[3] The systematic IUPAC (International Union of Pure and Applied Chemistry) name is 2-aminoethane-1-thiol, often written as 2-aminoethanethiol.[3]
  • Synonyms: The molecule is referenced by an extensive list of synonyms, including β-mercaptoethylamine, 2-mercaptoethylamine, decarboxycysteine, thioethanolamine, cysteinamine, mercamine, and the common abbreviation MEA.[1]
  • Brand Names: Cysteamine is marketed under several brand names, which correspond to specific formulations and routes of administration:
  • Oral Immediate-Release: Cystagon®.[1]
  • Oral Delayed-Release: Procysbi®.[1]
  • Ophthalmic Solutions: Cystaran® and Cystadrops®.[1]
  • Salt Forms: To enhance stability and facilitate formulation for clinical use, Cysteamine is administered as a salt. The specific salt form is a critical determinant of the product's application. The bitartrate salt is used for oral preparations (Cystagon® and Procysbi®), while the hydrochloride salt is utilized in ophthalmic solutions (Cystaran® and Cystadrops®).[1] This distinction is not arbitrary but a deliberate pharmaceutical engineering choice. Ophthalmic preparations demand specific properties, including sterility and a pH range that minimizes eye irritation (e.g., pH 4.1-4.5 for Cystaran® [9]), which are achievable with the hydrochloride salt. Conversely, oral formulations, especially delayed-release products, must be designed to survive the stomach's acidic environment, a goal met through the combination of the bitartrate salt and advanced enteric-coating technologies.

Chemical and Physical Properties

Cysteamine is an organosulfur compound characterized by the presence of both an amine (−NH2​) and a thiol (−SH) functional group on an ethane backbone.[3] This dual functionality is central to its biological activity.

  • Formula and Molecular Weight: The chemical formula for the free base is C2​H7​NS.[1] It has an average molecular weight of approximately 77.15 g·mol⁻¹ and a precise monoisotopic mass of 77.029919919 Da.[1]
  • Appearance and Solubility: In its solid form, Cysteamine is a white, water-soluble solid.[3] The hydrochloride salt, used in ophthalmic products, appears as a white crystalline powder or pellets and is freely soluble in water.[4]
  • Stability: The hydrochloride salt is noted to be stable but hygroscopic (readily absorbs moisture from the air) and is incompatible with strong oxidizing agents.[11] A critical chemical property is its propensity for rapid oxidation at room temperature, where the thiol group is converted to a disulfide. This instability poses a significant challenge for formulation, particularly for aqueous solutions, and dictates the strict storage requirements for products like Cystaran®.[12]

The extensive cataloging of Cysteamine across numerous databases (see Table 2.1) is a testament to its multifaceted history. It has been studied not only as a drug but also as a human and mouse metabolite, a metabolite of Escherichia coli, and a potential radiation protective agent.[4] This deep history predates its ultimate approval for cystinosis and explains the rich body of non-clinical data available for this structurally simple molecule.

PropertyValue / IdentifierSource(s)
DrugBank IDDB008471
CAS Number60-23-1 (free base)1
UNII5UX2SD1KE23
IUPAC Name2-aminoethane-1-thiol3
Chemical FormulaC2​H7​NS1
Average Molecular Weight77.15 g·mol⁻¹3
AppearanceWhite, water-soluble solid3
Melting Point95 to 97 °C3
Key Salt FormsBitartrate (Oral), Hydrochloride (Ophthalmic)1
PubChem CID60583
ChEMBL IDCHEMBL6023

Clinical Pharmacology

The clinical utility of Cysteamine is rooted in its specific biochemical interactions within the cell and its predictable pharmacokinetic behavior in the body. Its pharmacology has been refined over decades through the development of advanced formulations designed to optimize therapeutic effects and improve patient adherence.

Mechanism of Action

The therapeutic action of Cysteamine directly targets the molecular defect underlying cystinosis.

  • Pathophysiology of Cystinosis: Cystinosis is a rare, autosomal recessive lysosomal storage disease resulting from mutations in the CTNS gene. This gene encodes cystinosin, a protein that transports the amino acid cystine out of the lysosome. In the absence of functional cystinosin, cystine accumulates to toxic levels within lysosomes throughout the body, where it forms crystals. This crystallization process leads to progressive, irreversible cellular damage and multi-organ failure, most notably affecting the kidneys (nephropathic cystinosis) and eyes.[1]
  • Cystine Depletion via Thiol-Disulfide Interchange: Cysteamine is a small aminothiol that can enter the lysosome. Once inside, it engages in a thiol-disulfide interchange reaction with the accumulated cystine. This chemical reaction cleaves the disulfide bond of cystine (Cys−S−S−Cys) to form two new, more soluble molecules: one molecule of the amino acid cysteine (Cys−SH) and one molecule of a mixed disulfide of cysteine and Cysteamine (Cys−S−S−MEA).[1]
  • Restoration of Lysosomal Egress: The critical step in this mechanism is that both cysteine and the cysteine-cysteamine mixed disulfide can be transported out of the lysosome by other, unaffected transport proteins. This bypasses the defective cystinosin transporter, effectively depleting the lysosome of its toxic cystine load. This process, classified by the FDA as "Cystine Disulfide Reduction," prevents further crystal formation and slows the progression of organ damage.[1]

Pharmacodynamics

The pharmacodynamic effect of Cysteamine is directly measurable and serves as the primary guide for therapy. The goal of treatment is to reduce the body's cystine burden, and this is monitored using a key biomarker. The therapeutic target for oral Cysteamine is to maintain the white blood cell (WBC) cystine concentration below 1 nmol half-cystine/mg protein.[14] Achieving this target is directly correlated with preventing or delaying the long-term complications of cystinosis, including renal failure and growth retardation in children.[1] The decline in WBC cystine levels closely mirrors the plasma concentration of the drug, providing a reliable measure of its biological activity.[4]

Pharmacokinetics

The pharmacokinetic profile of Cysteamine varies significantly depending on the formulation, a factor that has driven the development of newer products with improved dosing schedules.

  • Absorption: When administered orally, Cysteamine is absorbed from the gastrointestinal tract. The immediate-release formulation (Cystagon®) reaches its maximum plasma concentration (Tmax​) in approximately 1.4 hours.[1] In contrast, the delayed-release formulation (Procysbi®), which utilizes enteric-coated microbeads, is designed to bypass the stomach and release the drug in the small intestine, resulting in a delayed Tmax​ of approximately 3 hours.[18] This delayed absorption is fundamental to its extended duration of action. Systemic absorption following ophthalmic administration is considered negligible.[1]
  • Distribution: Cysteamine is widely distributed throughout the body, as indicated by its large apparent volume of distribution (Vd​), which is reported to be approximately 198 L for the immediate-release form and 382 L for the delayed-release form.[1] A clinically significant feature is its ability to cross the blood-brain barrier, which is relevant for addressing potential central nervous system manifestations of cystinosis.[1]
  • Protein Binding: Cysteamine is moderately bound to plasma proteins (approximately 52%), primarily albumin.[1] This incomplete binding means a substantial fraction of the drug remains free in the plasma, which is an important consideration in cases of overdose, as it suggests that the drug may be effectively removed by hemodialysis.[1]
  • Metabolism and Elimination: There is limited published information regarding the specific metabolic pathways of Cysteamine. However, it is known to undergo extensive first-pass metabolism after oral administration.[1] It does not appear to be a significant inhibitor or inducer of the major cytochrome P450 (CYP) drug-metabolizing enzymes, suggesting a low potential for metabolic drug-drug interactions.[3] The plasma half-life of Cysteamine is relatively short, at approximately 3.7 hours, with a rapid plasma clearance of about 1.2 to 1.4 L/min.[1]

The development of Procysbi® represents a significant advancement in the clinical pharmacology of Cysteamine. The immediate-release formulation, Cystagon®, requires a strict and demanding dosing schedule of every 6 hours, around the clock, to maintain therapeutic WBC cystine levels.[18] This regimen poses a substantial burden on patients and caregivers, often leading to poor adherence and suboptimal long-term outcomes. By engineering a delayed-release formulation with a different pharmacokinetic profile, developers were able to create a product that could be administered every 12 hours. This change, while not altering the drug's fundamental mechanism, profoundly improved the feasibility of lifelong therapy, illustrating how pharmacokinetic innovation can directly translate into patient-centered benefits.

ParameterImmediate-Release (Cystagon®)Delayed-Release (Procysbi®)Source(s)
Tmax​ (Time to Peak)~1.4 hours~3 hours1
Cmax​ (Peak Concentration)37.72 ± 12.10 µmol/L27.70 ± 14.99 µmol/L1
AUC 0-12h (Total Exposure)192.00 ± 75.62 µmol*h/L99.26 ± 44.2 µmol*h/L1
Volume of Distribution (Vd​)~198 L~382 L1
Half-Life (t1/2​)~3.7 hours~3.7 hours1
Dosing FrequencyEvery 6 hoursEvery 12 hours18

Despite its long-standing use, the limited detailed knowledge of Cysteamine's metabolism represents a notable gap. While its major effects are well-characterized, a deeper understanding of the specific enzymes and pathways involved in its significant first-pass metabolism could provide valuable insights. Such knowledge might help explain inter-patient variability in drug response and tolerability, potentially allowing for more personalized dosing strategies and a better prediction of which patients are at a higher risk for adverse effects.

Therapeutic Indications and Clinical Use

Cysteamine's therapeutic applications are primarily focused on its approved orphan indication for cystinosis, but a growing body of research is exploring its potential in a range of other conditions, most notably in dermatology.

Approved Indications

Regulatory agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have approved Cysteamine for two distinct manifestations of cystinosis.

  • Nephropathic Cystinosis (Oral Formulations): Cysteamine bitartrate, available as immediate-release Cystagon® and delayed-release Procysbi®, is the global standard of care for the systemic treatment of nephropathic cystinosis.[1] It is indicated for use in both adults and children (as young as 1 year of age for Procysbi®) to deplete intracellular cystine, thereby delaying the progression of renal failure and mitigating the development of other systemic complications of the disease.[14]
  • Corneal Cystine Crystal Accumulation (Ophthalmic Formulations): Because oral Cysteamine does not effectively penetrate the avascular cornea, a local therapy is required to address the ocular manifestations of cystinosis.[13] Cysteamine hydrochloride is formulated as ophthalmic solutions, Cystaran® and Cystadrops®, which are indicated for the treatment of corneal cystine crystal deposits in adults and children.[1] These eye drops work by the same cystine-depleting mechanism, reducing the crystal burden in the cornea and alleviating symptoms such as photophobia and pain.[1]

Investigational and Off-Label Applications

The unique biochemical properties of Cysteamine have prompted investigation into its use for conditions beyond cystinosis.

  • Dermatology and Cosmeceuticals: This is the most rapidly expanding area of Cysteamine research, driven by its potent depigmenting effects. Its application in this field represents a classic example of drug repurposing, where a niche orphan drug is being adapted for a much more common condition.
  • Mechanism of Action: In the skin, Cysteamine functions as a tyrosinase inhibitor, downregulating the key enzyme in melanin synthesis. It also possesses powerful antioxidant properties, further contributing to its skin-lightening effects.[30]
  • Investigated Conditions: It is being used and clinically evaluated as a topical treatment for various hyperpigmentation disorders, including melasma, post-inflammatory hyperpigmentation (PIH), and solar lentigines (age spots).[3]
  • Formulation Innovation: A significant barrier to its topical use has historically been its instability and strong, unpleasant odor. The development of stabilized Cysteamine creams (e.g., Cyspera®) and novel formulations, such as a cysteamine-isobionicamide complex, has overcome these challenges, making it a viable cosmeceutical agent.[34] Clinical trials have shown that these topical formulations have efficacy comparable to gold-standard treatments like hydroquinone-based Kligman's formula but with a superior safety profile, making them particularly suitable for long-term use.[32]
  • Neurodegenerative Diseases: Cysteamine has been explored as a potential therapy for Huntington's disease (HD).
  • Preclinical Rationale: Promising results were observed in multiple mouse models of HD, where Cysteamine treatment improved motor symptoms and extended survival.[38]
  • Clinical Trial Results: This preclinical success led to a randomized, double-blind, placebo-controlled clinical trial in human patients with HD (the CYST-HD study). The trial confirmed that Cysteamine was safe and well-tolerated but failed to demonstrate a statistically significant benefit on the primary motor endpoint after 18 months of treatment.[38] While the primary outcome was not met, post-hoc analyses suggested a potential signal of benefit, and the study's authors concluded that definitive future studies were warranted.[39] This outcome highlights the well-known "translational gap" in neurodegeneration research, where promising preclinical findings often fail to translate into clear clinical efficacy in complex human diseases.
  • Other Research Areas: Cysteamine has received orphan drug designations for the treatment of Batten disease and pancreatic cancer, indicating early-stage interest in these areas.[40] Furthermore, preclinical research in animal models has demonstrated that Cysteamine can induce the regression of existing atherosclerotic lesions, suggesting a potential future role in cardiovascular disease.[41] Historically, it has also been investigated for its properties as a radioprotective agent and as an antidote for paracetamol (acetaminophen) toxicity.[42]

Formulations, Dosage, and Administration

Cysteamine is available in four distinct branded formulations—two oral and two ophthalmic—each with specific characteristics, dosing regimens, and administration instructions designed to meet different clinical needs. The evolution of these formulations reflects a clear trend toward reducing treatment burden and improving patient adherence in the management of a chronic, lifelong disease.

Oral Formulations (Cystagon® and Procysbi®)

Oral Cysteamine bitartrate is the mainstay of systemic therapy for nephropathic cystinosis.

  • Cystagon® (Immediate-Release Capsules):
  • Formulation: Supplied as 50 mg and 150 mg hard capsules containing Cysteamine bitartrate.[8]
  • Dosage and Administration: Cystagon® requires a demanding dosing schedule of every 6 hours around the clock to maintain therapeutic cystine depletion. The recommended maintenance dose for patients 12 years and older is 2 g/day, while for children under 12, it is 1.30 g/m²/day, divided into four doses. Therapy is initiated at a low dose (1/4 to 1/6 of the maintenance dose) and gradually increased over 4 to 6 weeks to improve tolerability.[14] To aid administration in young children (approximately under 6 years) who cannot swallow capsules, the capsules can be opened and the contents sprinkled on soft, non-acidic food like potatoes or mixed with milk.[44] Taking the medication with food can improve gastrointestinal tolerance.[1]
  • Procysbi® (Delayed-Release Capsules and Granules):
  • Formulation: Procysbi® is an advanced formulation designed to release Cysteamine bitartrate in the small intestine, not the stomach. It is available as 25 mg and 75 mg delayed-release capsules and as 75 mg and 300 mg delayed-release oral granules in packets. Both forms contain the same enteric-coated microbeads.[8]
  • Dosage and Administration: The key advantage of Procysbi® is its twice-daily (every 12 hours) dosing schedule, which significantly reduces the treatment burden compared to Cystagon®. The recommended maintenance dose is 1.3 g/m²/day, up to a maximum of 1.95 g/m²/day. For patients new to Cysteamine, the dose is started low and titrated up. For patients switching from Cystagon®, the total daily dose of Procysbi® is the same as their previous total daily dose of Cystagon®, divided into two doses.[14]
  • Food and Drug Interactions: Administration of Procysbi® is more complex than Cystagon®. To ensure the integrity of the enteric coating and proper absorption, it must be taken on an empty stomach (at least 2 hours after a meal and 30 minutes before the next). If necessary, a small amount (up to 4 ounces) of low-fat food may be consumed. High-fat foods and alcohol must be avoided near dosing times. The capsules can be swallowed whole or opened and the microbeads sprinkled on specific foods like applesauce or berry jelly.[1]

Ophthalmic Formulations (Cystaran® and Cystadrops®)

Local therapy with Cysteamine hydrochloride is essential for managing the corneal manifestations of cystinosis.

  • Cystaran® (Ophthalmic Solution, 0.44%):
  • Formulation: A sterile aqueous ophthalmic solution containing 0.44% Cysteamine (equivalent to 0.65% Cysteamine HCl).[9]
  • Dosage and Administration: Cystaran® requires very frequent administration: one drop in each eye every waking hour.[9]
  • Storage: Due to the instability of Cysteamine in solution, Cystaran® must be stored frozen. A bottle is thawed before use and is only stable for one week at room temperature, after which it must be discarded.[9]
  • Cystadrops® (Viscous Ophthalmic Solution, 0.37%):
  • Formulation: A more advanced, viscous ophthalmic solution containing 0.37% Cysteamine (equivalent to 0.55% Cysteamine HCl). The viscosity is increased by the addition of carmellose sodium, which prolongs the contact time of the drug on the corneal surface.[26]
  • Dosage and Administration: The improved formulation allows for a much less frequent dosing schedule of one drop in each eye four times per day.[26]
  • Storage: Cystadrops® is stored in a refrigerator before opening. Once opened, it can be kept at room temperature for up to 7 days.[51]
Brand NameActive SaltFormulation TypeAvailable StrengthsStandard Dosing FrequencyKey Administration/Storage Notes
Cystagon®Cysteamine BitartrateImmediate-Release Capsule50 mg, 150 mgEvery 6 hoursCan be opened and sprinkled on food; take with food to improve GI tolerance.
Procysbi®Cysteamine BitartrateDelayed-Release Capsule / GranulesCapsules: 25 mg, 75 mg Granules: 75 mg, 300 mgEvery 12 hoursMust be taken on an empty stomach; avoid high-fat food and alcohol.
Cystaran®Cysteamine HydrochlorideOphthalmic Solution0.44%Every waking hourMust be stored frozen; stable for only 1 week after thawing.
Cystadrops®Cysteamine HydrochlorideViscous Ophthalmic Solution0.37%4 times per dayStored refrigerated; stable for 7 days at room temperature after opening.

Comprehensive Safety Profile

While Cysteamine is a life-saving therapy for cystinosis, it is associated with a wide range of adverse effects and carries several significant warnings that require careful patient monitoring and management. It is important to note that Cysteamine does not have an FDA-mandated Black Box Warning.[54]

Adverse Reactions

The side effect profile of Cysteamine varies between its oral and ophthalmic formulations.

  • Oral Formulations (Cystagon® and Procysbi®):
  • Common Adverse Reactions: The most prevalent side effects are gastrointestinal and constitutional. These include nausea, vomiting, diarrhea, anorexia (loss of appetite), and abdominal pain. Systemic effects like lethargy, drowsiness, and fever are also common. A distinctive and often socially challenging side effect is an unpleasant sulfurous breath and skin odor, resulting from the metabolism of Cysteamine into volatile sulfur compounds.[3]
  • Serious Adverse Reactions: The most severe adverse reactions are detailed in the warnings below and include dose-dependent skin and bone lesions, severe rashes, gastrointestinal bleeding, and central nervous system toxicity.
  • Ophthalmic Formulations (Cystaran® and Cystadrops®):
  • Common Adverse Reactions: Side effects are typically localized to the eye. These include eye pain or irritation, ocular hyperemia (redness), photophobia (sensitivity to light), blurred vision, increased lacrimation (tearing), and headache.[3] Instillation site discomfort, such as sticky eyes, is also reported, particularly with the viscous Cystadrops® formulation.[51]

Warnings and Precautions

The prescribing information for oral Cysteamine includes several critical warnings regarding potentially severe or life-threatening toxicities.

  • Ehlers-Danlos-like Syndrome: This is a serious, dose-dependent toxicity. Patients treated with high doses of Cysteamine (typically exceeding the maximum recommended dose of 1.95 g/m²/day) can develop skin and bone lesions that resemble Ehlers-Danlos syndrome. Manifestations include molluscoid pseudotumors (purplish, hemorrhagic skin lesions), skin striae (stretch marks), bone fragility leading to fractures, scoliosis, and joint hyperextension.[3] This risk establishes a clear ceiling for safe dosing and necessitates regular, vigilant monitoring of the patient's skin and musculoskeletal system. If these signs develop, the dose must be reduced or the drug temporarily interrupted.[48]
  • Severe Skin Rash: Life-threatening cutaneous reactions, including erythema multiforme bullosa and toxic epidermal necrolysis (TEN), have been reported. The development of any severe skin rash requires the immediate and permanent discontinuation of Cysteamine therapy.[22]
  • Gastrointestinal Ulcers and Bleeding: Cysteamine can cause severe gastrointestinal symptoms, and cases of ulceration and bleeding have been reported.[3] Patients should be monitored for signs of GI toxicity, and a dose reduction may be necessary if severe symptoms occur.
  • Fibrosing Colonopathy: This is a rare but serious condition involving the formation of scar tissue and strictures in the colon, which has been reported with the postmarketing use of the delayed-release formulation, Procysbi®. The prescribing information specifically recommends that if this diagnosis is confirmed, Procysbi® should be permanently discontinued and the patient switched to the immediate-release formulation, Cystagon®.[22] This suggests a potential link to the formulation's excipients (e.g., methacrylic acid-ethyl acrylate copolymer) or its unique intestinal release profile, highlighting that drug delivery technology can introduce its own distinct safety risks.
  • Central Nervous System (CNS) Symptoms: Cysteamine has been associated with CNS effects, including seizures, lethargy, somnolence, depression, and encephalopathy.[3] Patients developing severe or progressive neurological symptoms may require dose adjustment or interruption of therapy.
  • Benign Intracranial Hypertension (Pseudotumor Cerebri): An increase in intracranial pressure has been reported in patients taking oral Cysteamine and in those using ophthalmic Cysteamine concurrently with oral therapy.[9] Patients should be monitored for symptoms such as headache, tinnitus, dizziness, and vision changes.
  • Hematologic and Hepatic Effects: Reversible leukopenia (low white blood cell count) and elevated alkaline phosphatase levels have been observed. Regular monitoring of blood counts and liver function is recommended.[16]

Contraindications

Cysteamine is contraindicated in the following populations:

  • Patients with a known hypersensitivity to Cysteamine or penicillamine, due to a potential for cross-reactivity.[23]
  • Women who are breast-feeding should not take oral Cysteamine.[44]

Overdosage

There is no specific antidote for Cysteamine overdose. An overdose may manifest as progressive lethargy. Management should be supportive, with particular attention to the cardiovascular and respiratory systems. Due to its relatively low plasma protein binding, hemodialysis may be effective in removing the drug from circulation.[1]

Drug and Food Interactions

The interaction profile of Cysteamine is notable in that it is almost entirely dictated by the pharmaceutical formulation of the product being used, rather than by the intrinsic metabolic properties of the Cysteamine molecule itself. This makes formulation-specific patient education a critical component of safe and effective therapy.

Drug-Drug Interactions

The most clinically significant drug-drug interactions involve the delayed-release formulation, Procysbi®, and its pH-sensitive enteric coating.

  • Drugs that Increase Gastric pH: Medications that reduce stomach acid, such as proton pump inhibitors (e.g., omeprazole, lansoprazole), H2-receptor antagonists (e.g., ranitidine), and antacids containing bicarbonate or carbonate, can interfere with Procysbi®.[1] The enteric coating on the Procysbi® microbeads is designed to remain intact in the highly acidic environment of the stomach and dissolve only in the more neutral pH of the small intestine. By increasing the stomach's pH, these acid-reducing drugs can cause the coating to dissolve prematurely, leading to a rapid, uncontrolled release of Cysteamine ("dose dumping") in the stomach. This can alter the drug's intended pharmacokinetic profile, potentially increasing the risk of gastrointestinal side effects and reducing its therapeutic efficacy over the 12-hour dosing interval.[3] To mitigate this interaction, patients are advised to administer Procysbi® at least one hour before or one hour after taking any medication containing bicarbonate or carbonate.[8]
  • Other Interactions: The immediate-release oral formulation (Cystagon®) and the ophthalmic formulations (Cystaran®, Cystadrops®) have no known clinically significant drug-drug interactions.[3] Cysteamine is not a major substrate, inhibitor, or inducer of the cytochrome P450 enzyme system, minimizing the risk of metabolic interactions.[3]

Drug-Food/Lifestyle Interactions

Similar to drug interactions, food and lifestyle interactions are highly specific to the formulation.

  • Alcohol: Consumption of alcohol is strongly discouraged for patients taking Procysbi®. Alcohol can accelerate the release of Cysteamine from the delayed-release microbeads, which can alter the drug's pharmacokinetics, reduce its effectiveness, and increase the risk of adverse effects.[3]
  • Food Interactions with Procysbi® (Delayed-Release):
  • Timing with Meals: To maximize absorption and ensure consistent drug release, Procysbi® should be taken on an empty stomach. The recommended schedule is to take the dose at least 2 hours after a meal and at least 30 minutes before the next meal.[16]
  • High-Fat Foods: High-fat meals should be avoided close to the time of dosing, as they can interfere with drug absorption.[19]
  • Administration with Food (if necessary): For patients who cannot tolerate Procysbi® on an empty stomach, it may be taken with a small amount (approximately 4 ounces or 1/2 cup) of food. This should be done consistently to maintain a stable absorption pattern.[8]
  • Grapefruit Juice: The prescribing information for Procysbi® specifies that it can be taken with fruit juice except grapefruit juice.[16]
  • Food Interactions with Cystagon® (Immediate-Release):
  • In direct contrast to Procysbi®, the immediate-release formulation Cystagon® can be administered with food. In fact, taking it with meals is often recommended to improve gastrointestinal tolerability.[1] The capsules can be opened and the contents sprinkled on certain foods for easier administration, particularly in children.[16]

This stark contrast in food interactions between the two oral formulations underscores the critical importance of patient counseling. A healthcare provider cannot simply advise on "Cysteamine interactions"; they must provide highly specific guidance tailored to the exact product the patient is using to ensure both safety and efficacy.

Regulatory History and Status

The regulatory journey of Cysteamine is a compelling narrative of pharmaceutical innovation, demonstrating how a single active molecule can be developed into multiple products over several decades to address the evolving needs of patients with a rare disease. This history is marked by key orphan drug designations and a series of strategic approvals in the United States and Europe.

Orphan Drug Designation

Given that cystinosis is a rare disease, affecting an estimated 2,000 to 3,000 people worldwide, Cysteamine products have consistently qualified for orphan drug designation.[18] This status provides regulatory and financial incentives to encourage the development of treatments for rare conditions.

  • Initial Designation: Cysteamine first received orphan designation from the FDA in 1991 for the treatment of nephropathic cystinosis, paving the way for the approval of Cystagon®.[73]
  • Designation Based on Clinical Superiority: The delayed-release formulation, Procysbi®, was also granted orphan designation, but on a different basis. Since it contained the same active drug for the same indication as the already-approved Cystagon®, the sponsor had to demonstrate a plausible hypothesis of "clinical superiority." This was successfully argued not on the basis of enhanced biochemical efficacy, but on its major contribution to patient care. The less frequent, twice-daily dosing schedule was shown to improve patient compliance and quality of life, a critical factor for a lifelong therapy. This was a landmark case that helped establish how patient-centric benefits could be valued in regulatory frameworks.[75]
  • Ophthalmic Formulations: The ophthalmic products, Cystaran® and Cystadrops®, were also designated as orphan drugs for treating the ocular manifestations of cystinosis, a distinct unmet need within this rare patient population.[25]

Approval Timelines

The approvals of the four major Cysteamine products occurred over a span of more than 25 years, each marking a significant step in improving the management of cystinosis.

  • Cystagon® (Immediate-Release Oral): This was the first Cysteamine product to gain approval, establishing the principle of cystine-depleting therapy. It was approved by the FDA on August 15, 1994, and by the EMA on June 23, 1997.[3]
  • Cystaran® (Ophthalmic Solution): This product addressed the unmet need for a topical treatment for corneal cystine crystals. It was approved by the FDA on October 2, 2012.[25]
  • Procysbi® (Delayed-Release Oral): This formulation was developed to improve patient adherence by reducing dosing frequency. It was first approved by the FDA on April 30, 2013, for adults and children aged 6 and older. This indication was subsequently expanded to younger age groups, reaching children as young as 1 year of age by 2017. A new oral granule formulation was approved in 2020. The EMA granted its approval on September 6, 2013.[3]
  • Cystadrops® (Viscous Ophthalmic Solution): This product improved upon Cystaran® by offering a more convenient dosing schedule. It was approved by the EMA on January 19, 2017, and by the FDA on August 19, 2020.[76]

This chronological progression clearly illustrates a sophisticated lifecycle management strategy. After the initial proof-of-concept with Cystagon®, subsequent research and development focused not on discovering a new molecule, but on innovating the delivery and formulation of the existing one to solve tangible clinical problems: first, the untreated ocular disease (Cystaran®), then the burdensome oral dosing schedule (Procysbi®), and finally, the burdensome ophthalmic dosing schedule (Cystadrops®).

Brand NameFormulationRegulatory BodyInitial Approval DateKey Indication Expansion(s)
Cystagon®Immediate-Release OralFDAAugust 15, 1994Management of nephropathic cystinosis in adults and children.
EMAJune 23, 1997Treatment of proven nephropathic cystinosis.
Procysbi®Delayed-Release OralFDAApril 30, 2013Initially for ages ≥6 years; expanded to ≥2 years (2015) and ≥1 year (2017).
EMASeptember 6, 2013Treatment of proven nephropathic cystinosis.
Cystaran®Ophthalmic SolutionFDAOctober 2, 2012Treatment of corneal cystine crystal accumulation.
Cystadrops®Viscous Ophthalmic SolutionEMAJanuary 19, 2017Treatment of corneal cystine crystal deposits (ages ≥2 years).
FDAAugust 19, 2020Treatment of corneal cystine crystal deposits in adults and children.

Clinical Trial Evidence and Future Directions

The clinical development of Cysteamine is supported by decades of research that have not only established its efficacy in cystinosis but are now paving the way for its use in new therapeutic areas.

Pivotal Clinical Trials

The approvals of Cysteamine formulations were based on a series of key clinical studies.

  • Nephropathic Cystinosis (Oral): Long-term observational studies and clinical trials have unequivocally demonstrated that early initiation and consistent use of oral Cysteamine preserves renal glomerular function, improves growth in children, and reduces or prevents the development of extra-renal complications like hypothyroidism.[16] The approval of Procysbi® was supported by a pivotal switch study which showed that the delayed-release formulation, administered every 12 hours, was non-inferior to the immediate-release formulation given every 6 hours in its ability to control WBC cystine levels.[18] This finding has been corroborated by real-world evidence, such as a retrospective Spanish study of nine patients who switched from immediate-release to extended-release Cysteamine. This study found that after the switch, renal function remained stable, growth improved in pediatric patients, hospitalizations were reduced, and tolerability was enhanced, with a decrease in reported gastrointestinal side effects and halitosis.[92]
  • Corneal Cystine Deposits (Ophthalmic): The efficacy of topical Cysteamine for the eyes was first established in placebo-controlled trials that showed a significant reduction in corneal crystal accumulation.[13] The approval of the more advanced viscous formulation, Cystadrops®, was based on a pivotal Phase III trial (the CHOC study) involving 32 patients. This study demonstrated that Cystadrops® (0.55% Cysteamine HCl equivalent) administered four times daily was significantly more effective at reducing corneal crystal density than a 0.10% aqueous Cysteamine solution. Efficacy was measured using in vivo confocal microscopy (IVCM), a sensitive imaging technique that allows for the quantification of crystals in different layers of the cornea.[52] Long-term follow-up data from the OCT-1 study showed that this efficacy was maintained over five years of treatment.[59]

Current Research and Future Outlook

The future of Cysteamine is evolving along two distinct paths. In cystinosis, it serves as the established standard of care, while in other fields, particularly dermatology, it is an emerging therapeutic agent with significant potential.

  • Benchmark in Cystinosis Research: Cysteamine's success has positioned it as the benchmark against which next-generation therapies for cystinosis are measured. For instance, ongoing Phase I/II clinical trials for novel treatments like cellular gene therapy (e.g., study DFT383) include a standard-of-care arm where patients continue to receive Cysteamine, using its well-documented effects as a comparator to evaluate the efficacy of the new intervention.[95]
  • Dermatology as a Major Growth Area: The most dynamic area of current research is the repurposing of Cysteamine as a topical agent for hyperpigmentation.
  • Evidence Base: A growing number of clinical trials are investigating stabilized Cysteamine creams for melasma and post-inflammatory hyperpigmentation.[33] Recent meta-analyses have concluded that its efficacy is comparable to gold-standard treatments like hydroquinone and modified Kligman's formula, but with a substantially better safety and tolerability profile, making it a more suitable option for long-term maintenance therapy.[32]
  • Anti-Aging Potential: A new and exciting frontier is the exploration of Cysteamine, particularly in combination with isobionic-amide, for skin rejuvenation and anti-aging. Early case series have reported promising results, with patients showing reductions in fine lines and wrinkles, improved skin texture and radiance, and an overall more youthful appearance.[35]
  • Need for Further Research: While promising, many of the current dermatological studies are limited by small sample sizes and short follow-up periods. There is a clear need for larger, more robust, long-term randomized controlled trials to definitively establish Cysteamine's role in the dermatology armamentarium and to fully understand its mechanisms of action in skin rejuvenation.[35]
  • Other Investigational Fields: While the clinical trial in Huntington's disease did not meet its primary endpoint, the possibility of a therapeutic benefit has not been entirely ruled out, leaving the door open for future, potentially more targeted, studies.[39] The preclinical findings related to atherosclerosis are also intriguing and warrant further investigation to determine if they can be translated into a clinical benefit for cardiovascular disease.[41]

This dual identity—as an established benchmark in its original orphan indication and as an emerging challenger in the much larger field of dermatology—defines the future trajectory of Cysteamine. It is a molecule whose therapeutic story is still being written.

Conclusion and Expert Recommendations

Cysteamine stands as an indispensable therapeutic agent in the management of cystinosis, a rare and devastating disease. Its role as a cystine-depleting agent has fundamentally altered the natural history of the condition, transforming it from a disease that was once fatal in childhood into a manageable, albeit chronic, illness. The evolution of its formulations—from the immediate-release Cystagon® to the delayed-release Procysbi® for systemic therapy, and from the hourly-dosed Cystaran® to the four-times-daily Cystadrops® for ocular therapy—is a testament to a patient-centric approach to pharmaceutical development. These innovations have not changed the drug's core mechanism but have profoundly improved its real-world effectiveness by reducing treatment burden and enhancing the potential for lifelong adherence.

However, the clinical benefits of Cysteamine are balanced by a significant and complex safety profile. The risk of severe, dose-dependent toxicities, such as Ehlers-Danlos-like syndrome, and formulation-specific risks like fibrosing colonopathy with Procysbi®, underscores the necessity for meticulous clinical management.

Looking forward, the therapeutic landscape for Cysteamine is bifurcating. Within cystinosis, it remains the firmly entrenched standard of care, serving as the benchmark against which potentially curative next-generation treatments, such as gene therapy, will be judged. Simultaneously, Cysteamine is being successfully repurposed as an emerging agent in the field of dermatology. By overcoming historical formulation challenges related to stability and odor, stabilized topical Cysteamine is proving to be a potent depigmenting agent with a safety profile that may be superior to traditional therapies for long-term use. Its potential in anti-aging applications further broadens its future horizons.

Based on this comprehensive analysis, the following recommendations are put forth:

  • For Clinicians: It is imperative to possess formulation-specific knowledge when prescribing Cysteamine. The stark differences in administration guidelines, food interactions, and safety profiles between immediate-release and delayed-release oral products demand precise patient education to ensure both safety and efficacy. Regular and vigilant monitoring for the known serious adverse effects, particularly skin and bone changes, is a critical component of risk mitigation and should be considered as important as laboratory monitoring of WBC cystine levels.
  • For the Research Community: While the efficacy of Cysteamine in cystinosis is well-established, a deeper investigation into its metabolic pathways could help elucidate the inter-patient variability in response and tolerability. In dermatology, there is a clear and pressing need to move beyond small-scale studies and conduct large, long-term, randomized controlled trials to definitively establish the efficacy and safety of topical Cysteamine for hyperpigmentation and skin rejuvenation, and to fully characterize its mechanisms of action in these new contexts.

Works cited

  1. Cysteamine: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 5, 2025, https://go.drugbank.com/drugs/DB00847
  2. Cysteamine - brand name list from Drugs.com, accessed August 5, 2025, https://www.drugs.com/ingredient/cysteamine.html
  3. Cysteamine - Wikipedia, accessed August 5, 2025, https://en.wikipedia.org/wiki/Cysteamine
  4. Cysteamine | C2H7NS | CID 6058 - PubChem, accessed August 5, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Cysteamine
  5. CAS 60-23-1 - Sigma-Aldrich, accessed August 5, 2025, https://www.sigmaaldrich.com/SE/en/search/60-23-1?focus=products&page=1&perpage=30&sort=relevance&term=60-23-1&type=cas_number
  6. cysteamine - PharmGKB, accessed August 5, 2025, https://www.pharmgkb.org/chemical/PA449171
  7. cysteamine - PharmGKB, accessed August 5, 2025, https://www.clinpgx.org/chemical/PA449171
  8. Cysteamine Uses, Side Effects & Warnings - Drugs.com, accessed August 5, 2025, https://www.drugs.com/mtm/cysteamine.html
  9. NDA 200740 Page 4 Reference ID: 3198343 ... - accessdata.fda.gov, accessed August 5, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/200740s000lbl.pdf
  10. Cysteamine | CAS#60-23-1 | aminothiol - MedKoo Biosciences, accessed August 5, 2025, https://www.medkoo.com/products/20399
  11. www.chemicalbook.com, accessed August 5, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB9337215.htm
  12. A randomized clinical trial of topical cysteamine disulfide (cystamine) versus free thiol (cysteamine) in the treatment of corneal cystine crystals in cystinosis - PubMed, accessed August 5, 2025, https://pubmed.ncbi.nlm.nih.gov/9758713/
  13. Cysteamine ophthalmic solution 0.44% for the treatment of corneal cystine crystals in cystinosis, accessed August 5, 2025, https://cystinosis.org/wp-content/uploads/2019/01/Huynh-Cystaran.pdf
  14. Clinical Policy: Cysteamine (Cystagon, Procysbi) - Coordinated Care, accessed August 5, 2025, https://www.coordinatedcarehealth.com/content/dam/centene/Coordinated%20Care/policies/pharmacy-policies/508-WA.PHAR.21-Cysteamine-(Cystagon-Procysbi)-01.12.2021.pdf
  15. 3301336 This label may not be the latest approved by FDA. For current labeling information, please visit https, accessed August 5, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203389s000lbl.pdf
  16. Cysteamine Monograph for Professionals - Drugs.com, accessed August 5, 2025, https://www.drugs.com/monograph/cysteamine.html
  17. Cysteamine - LiverTox - NCBI Bookshelf, accessed August 5, 2025, https://www.ncbi.nlm.nih.gov/books/NBK548701/
  18. 203389Orig1s000 - accessdata.fda.gov, accessed August 5, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203389Orig1s000ClinPharmR.pdf
  19. Enteric-Coated Cysteamine Bitartrate in Cystinosis Patients - PMC - PubMed Central, accessed August 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10385520/
  20. Cysteamine Completed Phase 1 Trials for Asthma Treatment | DrugBank Online, accessed August 5, 2025, https://go.drugbank.com/drugs/DB00847/clinical_trials?conditions=DBCOND0013565&phase=1&purpose=treatment&status=completed
  21. Taking PROCYSBI® (cysteamine bitartrate) delayed-release capsules, accessed August 5, 2025, https://www.procysbi.com/taking-procysbi
  22. PROCYSBI® (cysteamine bitartrate) Cystinosis Treatment | For HCPs, accessed August 5, 2025, https://www.procysbihcp.com/
  23. PROCYSBI® (cysteamine bitartrate) Delayed-release Capsules and Oral Granules, accessed August 5, 2025, https://www.procysbi.com/
  24. This label may not - accessdata.fda.gov, accessed August 5, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213491s000lbl.pdf
  25. SIGMA-TAU PHARMACEUTICALS, INC. RECEIVES FDA APPROVAL OF CYSTARAN™ (CYSTEAMINE OPHTHALMIC SOLUTION) 0.44% FOR TREATMENT OF COR - National Human Genome Research Institute (NHGRI), accessed August 5, 2025, https://www.genome.gov/Pages/Research/DIR/Sigma-Tau_Cystaran_Press_Release.pdf
  26. NDA 211302 Page 4 - accessdata.fda.gov, accessed August 5, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211302s000lbl.pdf
  27. Cystaran (Cysteamine) Eyedrops for Cystinosis Patients, accessed August 5, 2025, https://www.cystaran.com/what-is-cystaran-cysteamine/
  28. This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed August 5, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/200740s001lbl.pdf
  29. Cystadrops® (Cysteamine Ophthalmic Solution) Official Website, accessed August 5, 2025, https://www.cystadrops.com/
  30. What Are The Benefits Of Cysteamine For Melasma? - Kirsch Dermatology, accessed August 5, 2025, https://www.kirschderm.com/what-are-the-benefits-of-cysteamine-for-melasma/
  31. Cysteamine Unveiled: Harnessing Its Power in Skin Care | Clinikally, accessed August 5, 2025, https://www.clinikally.com/blogs/news/cysteamine-unveiled-harnessing-its-power-in-skin-care
  32. Clinical Efficacy of Cysteamine Application for Melasma: A Meta-Analysis - PMC, accessed August 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11642093/
  33. Study Details | Efficacy and Safety of Topical Cysteamine for Postinflammatory Hyperpigmentation | ClinicalTrials.gov, accessed August 5, 2025, https://clinicaltrials.gov/study/NCT05206318
  34. Topical Stabilized Cysteamine as a New Treatment for Hyperpigmentation Disorders: Melasma, Post-Inflammatory Hyperpigmentation, and Lentigines - PubMed, accessed August 5, 2025, https://pubmed.ncbi.nlm.nih.gov/34898155/
  35. New Cysteamine and Isobionicamide Formulation Can Rejuvenate Aging Skin, accessed August 5, 2025, https://www.dermatologytimes.com/view/new-cysteamine-and-isobionicamide-formulation-can-rejuvenate-aging-skin
  36. A Case Series With Cysteamine–Isobionicamide Complex: Clues for Skin‐Rejuvenating Activity - PMC, accessed August 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11736994/
  37. Cysteamine Isobionic-Amide Complex Versus Kligman's Formula for the Treatment of Melasma: Equal Efficacy and Rapid Onset of Action - JDDonline - Journal of Drugs in Dermatology, accessed August 5, 2025, https://jddonline.com/articles/cysteamine-isobionic-amide-complex-versus-kligmans-formula-for-the-treatment-of-melasma-equal-efficacy-and-rapid-onset-of-action-S1545961624P0009X/
  38. Cysteamine Protects Neurons from Mutant Huntingtin Toxicity - PMC, accessed August 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7039181/
  39. A randomized, double-blind, placebo-controlled trial evaluating cysteamine in Huntington's disease - PubMed, accessed August 5, 2025, https://pubmed.ncbi.nlm.nih.gov/28436572/
  40. Cystagon, Procysbi (cysteamine) dosing, indications, interactions ..., accessed August 5, 2025, https://reference.medscape.com/drug/cystagon-cysteamine-procysbi-342843
  41. Cysteamine Decreases Low‐Density Lipoprotein Oxidation, Causes Regression of Atherosclerosis, and Improves Liver and Muscle Function in Low‐Density Lipoprotein Receptor–Deficient Mice | Journal of the American Heart Association, accessed August 5, 2025, https://www.ahajournals.org/doi/10.1161/JAHA.120.017524
  42. Cysteamine: an old drug with new potential, accessed August 5, 2025, https://cystinosis.org/wp-content/uploads/2019/01/Besouw_2013_Drug_Discovery_Today.pdf
  43. Clinical Policy: Cysteamine (Cystagon, Procysbi) - NH Healthy Families, accessed August 5, 2025, https://www.nhhealthyfamilies.com/content/dam/centene/NH%20Healthy%20Families/Medicaid/pdfs/CP.PHAR.155%20Cysteamine.pdf
  44. Cystagon, INN-mercaptamine bitartrate - EMA, accessed August 5, 2025, https://www.ema.europa.eu/en/documents/product-information/cystagon-epar-product-information_en.pdf
  45. Cystagon | European Medicines Agency (EMA), accessed August 5, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/cystagon
  46. Package leaflet: Information for the user CYSTAGON 50 mg Hard Capsules CYSTAGON 150 mg Hard Capsules cysteamine bitartrate (merc, accessed August 5, 2025, https://www.medicines.org.uk/emc/files/pil.6233.pdf
  47. 213491Orig1s000 - accessdata.fda.gov, accessed August 5, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213491Orig1s000ChemR.pdf
  48. This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed August 5, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203389s027,213491s002lbl.pdf
  49. Cystaran (cysteamine hydrochloride) FDA Approval History - Drugs.com, accessed August 5, 2025, https://www.drugs.com/history/cystaran.html
  50. Cystaran (0.44% Cysteamine) Ophthalmic Cystinosis Treatment, accessed August 5, 2025, https://www.cystaran.com/hcp/about-cystaran-ophthalmic-cystinosis-treatment/
  51. Cystadrops 3.8 mg/mL eye drops solution - Summary of Product ..., accessed August 5, 2025, https://www.medicines.org.uk/emc/product/8505/smpc
  52. Long-term follow-up of cystinosis patients treated with 0.55% cysteamine hydrochloride, accessed August 5, 2025, https://bjo.bmj.com/content/105/5/608
  53. Cystaran, Cystadrops (cysteamine ophthalmic) dosing, indications, interactions, adverse effects, and more - Medscape Reference, accessed August 5, 2025, https://reference.medscape.com/drug/cystaran-cystadrops-cysteamine-ophthalmic-999777
  54. cysteamine bitartrate delayed-release - Procysbi - Molina Healthcare, accessed August 5, 2025, https://www.molinahealthcare.com/providers/wa/medicaid/resource/PDF/prsenra-cysteamine-bitartrate-mcp219.pdf
  55. Cysteamine Side Effects: Common, Severe, Long Term - Drugs.com, accessed August 5, 2025, https://www.drugs.com/sfx/cysteamine-side-effects.html
  56. Cystagon Advanced Patient Information - Drugs.com, accessed August 5, 2025, https://www.drugs.com/cons/cystagon.html
  57. Cysteamine Ophthalmic: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed August 5, 2025, https://www.rxlist.com/cysteamine_ophthalmic/generic-drug.htm
  58. Cystaran Eyedrops for Cystinosis | Treat Crystals in Eye, accessed August 5, 2025, https://www.cystaran.com/
  59. Cystadrops® (Cysteamine Ophthalmic Solution) Efficacy and Safety, accessed August 5, 2025, https://www.cystadrops.com/hcp/clinical-data-safety/
  60. Pediatric Postmarketing Pharmacovigilance and Drug Utilization Review (Procysbi (cysteamine bitartrate)) - FDA, accessed August 5, 2025, https://www.fda.gov/media/113582/download
  61. Important Safety Information | PROCYSBI® (cysteamine bitartrate), accessed August 5, 2025, https://www.procysbi.com/important-safety-information
  62. Cystagon, INN-mercaptamine bitartrate, accessed August 5, 2025, https://ec.europa.eu/health/documents/community-register/2013/20130912126407/anx_126407_en.pdf
  63. Horizon Therapeutics plc Announces U.S. FDA Approval of New Dosage Form for PROCYSBI® (Cysteamine Bitartrate) Delayed-Release Oral Granules - BioSpace, accessed August 5, 2025, https://www.biospace.com/horizon-therapeutics-plc-announces-u-s-fda-approval-of-new-dosage-form-for-procysbi-cysteamine-bitartrate-delayed-release-oral-granules
  64. Cysteamine : Indications, Uses, Dosage, Drugs Interactions, Side effects, accessed August 5, 2025, https://medicaldialogues.in/generics/cysteamine-2723401
  65. Cysteamine (Cystagon, Procysbi): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD, accessed August 5, 2025, https://www.webmd.com/drugs/2/drug-164325-2183/procysbi/details
  66. Cystagon - NPS MedicineWise, accessed August 5, 2025, https://www.nps.org.au/medicine-finder/cystagon-capsules
  67. PATIENT INFORMATION PROCYSBI® (Pro-CIS-bee) (cysteamine bitartrate) delayed-release capsules and delayed-release oral granules, accessed August 5, 2025, https://www.procysbi.com/-/media/Themes/Horizon/procysbi-com/procysbi-com/Document/PROCYSBI-Patient-Information.pdf
  68. Dosing and Prescribing PROCYSBI® (cysteamine bitartrate) - for HCPs, accessed August 5, 2025, https://www.procysbihcp.com/starting-procysbi/dosing-and-administration
  69. Cysteamine Alternatives Compared - Drugs.com, accessed August 5, 2025, https://www.drugs.com/compare/cysteamine
  70. www.amgen.ca, accessed August 5, 2025, https://www.amgen.ca/about/-/media/themes/corporateaffairs/redesign/amgen-ca/amgen-ca/pdf/products/en/en-2025-04-17-procysbi-pm-hc-approved.pdf
  71. Cysteamine (oral route) - Side effects & dosage - Mayo Clinic, accessed August 5, 2025, https://www.mayoclinic.org/drugs-supplements/cysteamine-oral-route/description/drg-20068629
  72. Cysteamine (Cystagon, Procysbi): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD, accessed August 5, 2025, https://www.webmd.com/drugs/2/drug-10707/cystagon-oral/details
  73. Search Orphan Drug Designations and Approvals - FDA, accessed August 5, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=55690
  74. Search Orphan Drug Designations and Approvals - FDA, accessed August 5, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=13986
  75. FDA Was For PROCYSBI Orphan Drug Designation Based on Clinical Superiority Before It Was Against It . . . And Then For It Again, accessed August 5, 2025, https://www.thefdalawblog.com/2014/08/fda-was-for-procysbi-orphan-drug-designation-based-on-clinical-superiority-before-it-was-against-it/
  76. Cystadrops | European Medicines Agency (EMA), accessed August 5, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/cystadrops
  77. Cysteamine hydrochloride - Orphanet, accessed August 5, 2025, https://www.orpha.net/en/drug/substance/165069
  78. Generic Cystagon Availability - Drugs.com, accessed August 5, 2025, https://www.drugs.com/availability/generic-cystagon.html
  79. Generic Cystaran Availability - Drugs.com, accessed August 5, 2025, https://www.drugs.com/availability/generic-cystaran.html
  80. Rare Disease Report: Raptor's Cysteamine Capsule Now Approved for Children, accessed August 5, 2025, https://globalgenes.org/blog/rare-disease-report-raptors-cysteamine-capsule-now-approved-for-children/
  81. www.accessdata.fda.gov, accessed August 5, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203389Orig1s000TOC.cfm#:~:text=Approval%20Date%3A%204%2F30%2F2013
  82. Procysbi (cysteamine bitartrate) FDA Approval History - Drugs.com, accessed August 5, 2025, https://www.drugs.com/history/procysbi.html
  83. Procysbi | European Medicines Agency (EMA), accessed August 5, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/procysbi
  84. Search Orphan Drug Designations and Approvals - FDA, accessed August 5, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=231006
  85. Cystadrops (cysteamine hydrochloride) FDA Approval History - Drugs.com, accessed August 5, 2025, https://www.drugs.com/history/cystadrops.html
  86. Generic Cystadrops Availability - Drugs.com, accessed August 5, 2025, https://www.drugs.com/availability/generic-cystadrops.html
  87. Cystadrops® (cysteamine) – New drug approval, accessed August 5, 2025, https://professionals.optumrx.com/publications/library/drugapproval_cystadrops_2020-0824.html
  88. APPLICATION NUMBER: - 211302Orig1s000 SUMMARY REVIEW - accessdata.fda.gov, accessed August 5, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/211302Orig1s000SumR.pdf
  89. Study Details | Use of Cysteamine in the Treatment of Cystinosis - ClinicalTrials.gov, accessed August 5, 2025, https://clinicaltrials.gov/study/NCT00359684
  90. Effects of long-term cysteamine treatment in patients with cystinosis ..., accessed August 5, 2025, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394685/
  91. Clinical Policy: Cysteamine oral (Cystagon, Procysbi) - Ambetter Health, accessed August 5, 2025, https://www.ambetterhealth.com/content/dam/centene/Superior/policies/pharmacy-policies/Cysteamine%20ral%20(Cystagon,%20Procysbi)%20(CP.PHAR.155)%20(PDF).pdf
  92. Switching from immediate- to extended-release cysteamine in patients with nephropathic cystinosis: from clinical trials to clinical practice - PubMed, accessed August 5, 2025, https://pubmed.ncbi.nlm.nih.gov/38633840/
  93. Switching from immediate- to extended-release cysteamine in patients with nephropathic cystinosis: from clinical trials to clinical practice | Clinical Kidney Journal | Oxford Academic, accessed August 5, 2025, https://academic.oup.com/ckj/article-abstract/17/4/sfae049/7623602
  94. Results - Clinical Review Report: Cysteamine 3.8 mg/mL ophthalmic solution (Cystadrops), accessed August 5, 2025, https://www.ncbi.nlm.nih.gov/books/NBK546766/
  95. Current Clinical Trials - Cystinosis Research Foundation, accessed August 5, 2025, https://www.cystinosisresearch.org/current-clinical-trials/
  96. (PDF) Efficacy and Safety of Cysteamine in Melasma in Patients of Skin of Colour: A Brief Report - ResearchGate, accessed August 5, 2025, https://www.researchgate.net/publication/389412600_Efficacy_and_Safety_of_Cysteamine_in_Melasma_in_Patients_of_Skin_of_Colour_A_Brief_Report
  97. Efficacy and safety of cysteamine-isobionicamide complex in postinflammatory hyperpigmentation: A 16-week, randomized, double-blinded, vehicle-controlled trial - ResearchGate, accessed August 5, 2025, https://www.researchgate.net/publication/376977349_Efficacy_and_safety_of_cysteamine-isobionicamide_complex_in_postinflammatory_hyperpigmentation_A_16-week_randomized_double-blinded_vehicle-controlled_trial
  98. Clinical Efficacy of Cysteamine Application for Melasma: A Meta-Analysis - MDPI, accessed August 5, 2025, https://www.mdpi.com/2077-0383/13/23/7483
  99. Efficacy and Safety of Cysteamine in Melasma in Patients of Skin of Colour: A Brief Report, accessed August 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11927990/

Published at: August 5, 2025

This report is continuously updated as new research emerges.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.